2020年11月13日

바이오스펙테이터기사입력:2020-11-13十四36 |수정:2020-11-13由Sungmin十四36金洞察力Equity Partners,合作伙伴的投资,和风筝创业基金会参与该基金对韩国基于ai领域的主要参与者RWD / RWE休息平台Linewalks,医疗大数据公司9日宣布,它已经吸引了首轮投资共计50亿韩元。洞察力Equity Partners,合作伙伴的投资,和风筝企业家基金会参与这项投资。此外,Linewalks迄今获得了总投资70亿韩元的包括天使投资和种子投资从Kakao投资19亿韩元。这项投资将用于扩大和建筑MDwalks,真实的证据(RWE)平台,和保护领域的专业数据,医疗,和统计数据。它解释说,他们将把重点放在数据利用率,分析专业知识、安全的未来竞争力和效率。Linewalks公司提供数据分析服务结合人工智能技术与卫生保健大数据。特别是,他们正在开发一个平台来扩大使用真实世界的证据(RWE),分析真实世界数据(RWD)积累实际治疗网站发现临床证据的新功效和利益/商用药物的副作用。这里的概念是不同于随机对照试验(RCT)进行药物的批准。在临床研究中,小规模的患者在一个被控制的环境中学习,有一个限制在观察期内完全领会的副作用。因此,自2010年以来,监管机构在美国和欧洲批准新药和分析基于RWE的副作用。 Currently, Linewalks is conducting research with domestic and foreign pharmaceutical companies and research institutes based on actual use data held by Seoul Asan Medical Center and Health Insurance Review and Assessment Service. The company explains that it is laying the foundation for technology development to provide an advanced artificial intelligence analysis platform in time for Real World Evidence to be applied in the process of developing new drugs in the future. Linewalks is focusing on two major areas of data analysis. First, artificial intelligence technology analyzes the treatment efficacy by searching the treatment patterns of the characteristic patient group in Electronic Medical Records. The U.S. Food and Drug Administration (FDA) accepted RWE from the electronic medical record data as a main evidence; an example of applying it to the development of new drugs is Amgen's "Blincyto" which was approved through the FDA's expedited review in 2014. Linewalks plans to significantly expand the RWE project to support major pharmaceutical partners, and is focusing on research in the oncology, particularly lung cancer, breast cancer, and pancreatic cancer. The second area they are focusing on is the field of artificial intelligence (AI) medical devices. Linewalks has been developing artificial intelligence prediction technology that utilizes data from patients with cardiovascular diseases by participating in the 'Dr. Answer' project, an artificial intelligence-based precision medical solution, under the supervision of the Ministry of Science and ICT for the past three years. Based on this technology, artificial intelligence medical devices will be developed to detect the possibility of severe acute diseases in high-risk cardiovascular patients. The medical device, which can help with diagnosis and prognosis management at the actual medical site, aims to complete clinical trials and licensing procedures by 2022. YongHyun Cho, CEO of Linewalks, said, "Through this investment, we can lay the foundation for spreading Linewalks' data analysis capabilities to the medical community and support RWE-specific retrospective clinical data analysis more efficiently. Based on Lineworks' Real World Evidence platform, MDWalks, we plan to provide high-quality analysis services to hospitals, pharmaceutical companies, and medical device companies." Soyong Sung, director of Insight Equity Partners, who led the investment, said that he made the investment by saying, "We believe that it is a leading company that can analyze RWD with AI-based technology in the RWE field where rapid growth is expected." Sumin Sim, Managing Director of Partners Investments, said, “The use of RWD and RWE for post-marketing of pharmaceuticals and medical devices, approval revisions, expansion of indications, and establishment of new product development strategies is a field with great potential that has just started to grow.” Linewalks, as a domestic leader in the RWD/RWE platform field, is currently focusing on analyzing complex and unmet medical needs such as cancer using medical data in large hospitals.” by Sungmin Kim press@bios.co.kr